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26 years period was associated with 18,59 LYG. At the same time use of autocoded 
blood glucose meters was associated with 18,92 LYG. In case of using autocoded 
meters instead of using manually coding meters patients obtained 0,33 LYG more 
(120 days). ConClusions: Obtained results showed that difference in glucose 
measurement errors between manually coded and autocoded blood glucose meters 
can lead to the difference in long-term outcomes in diabetes treatment.
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objeCtives: Type 2 diabetes mellitus (T2DM) is a chronic disease associated 
with increased risk of cardiovascular (CV) and microvascular complications. 
Improvements in blood pressure and cholesterol control have resulted in a reduc-
tion in CV event rates in clinical practice. The objective of this study was to assess 
the relationship between increased life expectancy, due to reduction in CV event 
rates, and the risk of microvascular disease for a range of glycemic control lev-
els. Methods: A lifetime analysis was conducted using the CORE diabetes model 
(CDM). Newly diagnosed T2DM simulated patients aged 52 years at baseline with 
HbA1c 7.1%, SBP 135.1 mmHg, total cholesterol: HDL 5.2 mmol/l were modelled. The 
impact of HbA1c on microvascular complications was assessed by running the CDM 
with baseline HbA1c ±1% for scenario 1: 100% of patient receiving CV risk factor 
management; and scenario 2: no CV risk factor management. Results: Improved 
CV risk factor management reduced the predicted cumulative incidence of fatal 
myocardial infarction (MI) from 27% to 18%, increasing life expectancy by an aver-
age of 2 years. For scenario 1, baseline HbA1c +1% versus -1% was associated with 
a 20%, 11% and 4% increase in microalbuminuria (MA), gross proteinuria (GRP) and 
end stage renal disease (ESRD), respectively; for scenario 2, the increase was 15.5% 
for MA, 7.6% for GRP and 2.5% for ESRD. Cumulative incidence of neuropathy ranged 
from 68.4% (baseline HbA1c +1%) to 42.1% (baseline HbA1c -1%) for scenario 1 and 
from 65.2% (baseline HbA1c +1%) to 39.7% (baseline HbA1 c-1%) for scenario 2. 
Cumulative retinopathy rates were similar across both scenarios: 56.7% versus 56.0% 
for scenarios 1 and 2, respectively. ConClusions: This modeling study suggests 
that improvements in blood pressure and cholesterol management may result in 
increased rates of microvascular complications, in particular renal disease, over the 
long term as patient survival increases.
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A systemAtic Review AnD netwoRk metA-AnAlysis Assessing the 
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objeCtives: A significant proportion of patients with type-2-diabetes mellitus 
(T2DM) are unable to take Metformin as recommended first-line therapy due to 
gastrointestinal intolerance or contraindications such as chronic kidney disease. 
In contrast to combination therapy no network meta-analysis (NMA) has been 
undertaken for oral anti-diabetic drugs (OAD) as monotherapy in this population - 
particularly with respect to gliptins and sulfonylureas as second-line options. The 
purpose of this study is to assess the comparative effectiveness and tolerability of 
gliptins versus sulfonylureas in terms of glycated hemoglobin (HbA1c), body weight 
and hypoglycemia. Methods: A systematic review was conducted searching bib-
liographic databases, reports of regulatory authorities and clinical trial registries 
through July 2012 to identify randomized controlled trials in adult T2DM patients 
receiving at least 12 weeks of OAD monotherapy or placebo. A Bayesian NMA was 
performed to yield mixed treatment comparisons. Consistency was examined by the 
node split method. Results: A total of 62 studies enrolling 21,302 patients informed 
the entire network. Due to their improved model fit estimates from random effect 
models are reported to account for heterogeneity across the set of studies. After a 
mean follow-up of 32 weeks, the difference in mean HbA1c was 0.26, 0. 95 credible 
interval (CrI0.95): [0.1; 0.42], in favour of sulfonylureas. However, gliptins induced 
weight loss (difference in means: -1.21 kg; CrI0.95: [-1.57; -0.84] ) and were associated 
with a considerably lower incidence of any hypoglycemia compared to sulfonylureas 
(odds ratio: 0.22; CrI0.95: [0.15; 0.31] ). All effect estimates were statistically significant 
and consistent in terms of combining direct and indirect evidence. ConClusions: 
This is the first network assessing OAD monotherapy that can readily be extended 
to emerging therapies. With regard to glycemic control gliptins were slightly inferior 
to sulfonylureas, whereas they positively affected body weight and risk of hypogly-
cemia, confirming their role in second-line monotherapy.
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objeCtives: Inadequate glycemic, blood pressure (BP), and low-density lipopro-
tein (LDL) control among persons with type 2 diabetes mellitus (T2DM) increases 
the risk of T2DM-related complications, which require more intensive and costly 
therapy. Extending on a recently-conducted study in Dubai, UAE, we assessed levels 
of glycemic, LDL, and BP control, and estimated the proportion of those meeting 
offers similar or reduced HbA1c reduction, had comparable significant weight loss 
to other SLGT-2s and GLP-1s, and appeared to have a superior weight loss profile 
compared with DPP-4s and TZDs.. No increased risk of adverse events were observed 
for empagliflozin compared with placebo and other ADs.
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objeCtives: The aim of the present network meta-analysis is to compare the effi-
cacy and safety of empagliflozin versus other antidiabetic drugs used in third line 
for the treatment of patients with type 2 diabetes mellitus (T2DM). Methods: We 
conducted a systematic review randomized controlled trials (RCTs) and Bayesian 
network meta-analysis to establish the comparative efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s, and TZDs. RCTs enrolling subjects with T2DM inadequately con-
trolled on metformin plus sulfonylurea were included. The principal outcome of 
this analysis was the effect of these drugs on HbA1c, weight, systolic blood pres-
sure (SBP), incidence of hypoglycaemia and urinary tract infections (UTIs) at 24 
weeks. Results: From 6969 abstracts, 13 were included in the analysis. No RCTs 
involving TZDs were identified. Compared with placebo, mean changes in HbA1c 
were -0.65% [95% confidence interval (CI) -1.59 to -0.08%] and -0.60% [95%CI -1.14 to 
-0.14%] for empagliflozin 10mg and 25mg. No significant differences were detected 
between interventions. Mean changes in weight with empagliflozin 10mg and 25mg 
were -1.77 [95%CI -2.19 to -1.35) and -2.00 (95%CI -2.44 to -1.57), respectively. Mean 
weight losses were fairly similar across SLGT-2s and GLP-1s ranging between -1.26 
to -2.12. All DPP-4s were associated weight gains, ranging form 0.33 to 0.98, of which 
most were statistically significant. SBP data were only available for SGLT-2s and 
DPP-4s. Empagliflozin 10mg and 25mg compared with placebo had statistically sig-
nificant reductions of -2.70 and -2.09. All interventions (except exenatide) yielded 
relative risk of hypoglycaemia greater than 1.00. For UTIs, no differences were found 
between SLGT-2s or DPP-4s and placebo. ConClusions: Compared with other 
SGLT-2s, DPP-4s, and GLP-1s, empagliflozin generally offers similar HbA1c control 
at week 24, an advantageous profile in weight loss and reduction of SBP, as well as 
similar safety profile.
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objeCtives: To compare the efficacy and safety of empagliflozin versus other sec-
ond-line treatment for patients with type 2 diabetes mellitus (T2DM). Methods: A 
systematic review and Bayesian network meta-analysis were performed to identify 
randomized controlled trials (RCTs) assessing the efficacy and safety of SGLT-2s, 
DPP-4s, GLP-1s, TZDs, and SUs in patients with T2DM. RCTs enrolling subjects with 
T2DM inadequately controlled with metformin monotherapy were included. The 
principal outcomes were HbA1c, weight, systolic blood pressure (SBP), hypoglycae-
mia, and urinary tract infections (UTIs) at 24 weeks. Results: Forty-eight RCTs 
were included. The mean differences (MD) in HbA1c were -0.56% [95% confidence 
interval (CI) -1.06% to -0.08%] and -0.64% [95%CI -1.14 to -0.14%] for Empagliflozin 
10mg and 25mg vs placebo. All other interventions yielded similar reductions and 
no significant differences were detected between interventions. Empagliflozin 10mg 
and 25mg significantly changed patients’ weight by -1.63kg (95%CI -2.66 to -0.64) 
and -2.01kg (95%CI -3.02 to -1.02), versus placebo. Other SLGT-2s had similar MDs, all 
DPP-4s had no change, and GLP-1s fell in between. All SUs and TZDs were associated 
with significant weight gain versus placebo. For SBP, the MDs for Empagliflozin 10mg 
and 25mg versus placebo were -4.09mmHg (95%CI -6.97 to -1.18) and -4.81mmHg 
(95%CI -7.69 to -2.00). No significant differences between Empagliflozin and other 
interventions were detected. Incidence of hypoglycaemia for empagliflozin 10 and 
25 mg relative to placebo was 2.71 [95%CI 0.46 to 11.44] and 1.97 [95%CI 0.23 to 9.57], 
respectively. No significant differences were detected between emplagliflozin and 
other interventions. For UTIs, all yielded relative risks close to 1.00 when compared 
with placebo. ConClusions: Compared with other SGLT-2s, DPP-4s, GLP-1s, TZDs, 
and SUs, empagliflozin offers similar HbA1c control at 24 weeks, a marked reduc-
tion in weight compared with DPP-4s, TZDs, and SUs, and a similar safety profile 
as other interventions.
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objeCtives: To obtain long-term clinical outcomes of using manually coded 
and autocoded blood glucose meters in diabetes treatment in the Russian 
Federation. Methods: The model used in this study analyzed the influence of 
errors in blood glucose measurements (due to using manually or autocoded glu-
cose meters) on the treatment of patients with Type 1 and Type 2 diabetes during 
the 26 years period (the life-time period). Life years gained (LYG) was chosen as an 
outcome measure in assessment of health intervention. Calculation of LYG was 
based on prior clinical studies that evaluated glucose meters’ errors in glucose 
level measurements and risk of complications associated with blood glucose level. 
Data for patients with diabetes was obtained from prior epidemiological studies 
that had been provided in Russian Federation. Results: Use of manually coded 
blood glucose meters in the analyzed population with median age of 53 years during 
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objeCtives: Network meta-analyses (NMA) provide estimates of comparative 
efficacy for multiple treatments based on an analysis of connected networks of 
trial comparisons. A key concern is the comparability of treatment effect estimates 
from different trials. Where there is both indirect and direct evidence for one or 
more comparisons (‘loops’ in the network) it is possible to evaluate empirically the 
‘consistency’ of the network. Methods: A variety of methods have been proposed 
to examine inconsistency including: (i) node-splitting where the direct and indirect 
estimates are compared across the network (ii) comparison to an ‘inconsistency’ 
model where estimates for each treatment comparison are allowed to be inde-
pendent, (iii) inclusion of treatment by design interaction terms, (iv) investigation 
of residual deviance estimates for individual trial arms, and (v) investigation of 
mixed predictive p-values. We compare the implementation and, most impor-
tantly, the interpretation of these methods using a previously published NMA in 
type 2 diabetes. In this analysis HbA1c was compared across six treatments in 
a network of 22 studies with multiple ‘loops’. Results: The methods agreed in 
showing the presence of inconsistency with the network. For example, the incon-
sistency model showed an improved fit (DIC -62.35) compared to the consistency 
model (DIC -60.25). The node splitting method identified statistically significant 
inconsistency in two treatment arcs (liraglutide 1.8mg vs placebo and liraglutide 
1.8mg vs exenatide QW). ConClusions: The alternative methods vary in their 
ability to provide an omnibus ‘test’ of inconsistency across the network and their 
ability to identify which parts of the network contain inconsistencies. We highlight 
that none of the methods alone can identify individual studies as being the cause 
of inconsistencies and argue that we need to consider the whole structure of the 
network and the characteristics of the studies (in terms of treatments, subjects 
and design) within the network.
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objeCtives: To investigate HbA1c-reduction by baseline BMI in patients treated 
with canagliflozin or sitagliptin, using clinical trial and electronic medical record 
(EMR) data. Methods: Patient-level data from two randomised controlled tri-
als (RCTs) were used to explore HbA1c-reduction from baseline after 52 weeks 
treatment with canagliflozin (100/300mg) or sitagliptin (100mg) by baseline 
BMI. Ordinary least squares (OLS) regression was performed with HbA1c, BMI, 
eGFR and demographics as covariates, in patients with metformin (MET) or 
metformin+glimepiride (MET+SU) background therapy. EMR-data (UK General 
Practitioner data from CPRD) on HbA1c over time in patients treated with sitag-
liptin were analysed by background therapy using repeated measures analysis, 
with baseline BMI, HbA1c and demographics as covariates. Results: In both RCTs 
sitagliptin showed a decreasing HbA1c-reduction by increasing baseline BMI, while 
efficacy of canagliflozin was independent of BMI. The estimated HbA1c-reduction 
(%) from baseline for sitagliptin in patients with baseline BMI of 25 vs. 40 varied 
between -0.87 to -0.58 (MET; Δ = 0.29, p= 0.01) and -0.87 to -0.54 (MET+SU; Δ = 0.33, 
p= 0.0014), while a non-significant increase in HbA1c-reduction was observed in 
high BMI-patients in all canagliflozin-arms (Δ between -0.04 and -0.07). EMR-
data showed similar decreasing effectiveness of sitagliptin in high BMI-patients. 
Estimated HbA1c-reduction (month 10; baseline HbA1c 9%) was significantly less 
(MET: Δ = 0.30, MET+SU: Δ = 0.35, p< 0.0001) in patients with BMI 40 vs. 25. No data 
for canagliflozin were yet available. Lower efficacy of sitagliptin in obese patients 
has been previously reported in the literature. ConClusions: RCT and EMR-
data consistently show that the relative efficacy of anti-diabetic treatments may 
depend on baseline BMI. Reduced efficacy of sitagliptin and DPP-4 inhibitors in 
general in obese patients may be explained by a higher degree of insulin-resist-
ance. Efficacy of canagliflozin is independent of BMI, due to its insulin-independ-
ent mechanism of action. Patients’ BMI should be taken into account to select 
effective therapeutic options for patients with T2DM.
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objeCtives: Comparative effectiveness of new oral anti-diabetic drugs in primary 
care practice remains poorly characterized. This presentation focus on the relevant 
statistical methods used to handle common potential bias related to real-world 
observational designs. Methods: Multicenter, longitudinal, observational study, 
conducted in primary care in France. Participating physicians were to include 
adult type 2 diabetes patients initiating a treatment with metformin and sitag-
liptin dual therapy (M-Sit group) or metformin and sulfonylurea dual therapy 
(M-SU group). Planned follow-up period was three years. The primary endpoint 
was the treatment maintenance duration, from initiation of dual therapy to a 
strict change, defined as the addition, replacement or withdrawal of an agent used 
for initial dual therapy. Survival Kaplan-Meier analysis, multivariate Cox model 
adjusted on the propensity score in order to limit bias due to baseline imbalance 
between the two groups and sensitivity analyses including multiple imputations to 
deal with missing data have been performed. Results: A total of 3 453 patients 
have been analyzed: 1 874 in the M-Sit group and 733 in the M-SU group. 
In the principal analysis, the median treatment maintenance duration was 
20.2 months in the M-SU group and 43.2 months in the M-Sit group (p < 0.0001). 
guideline targets, among a cohort of individuals treated for T2DM in Riyadh, Saudi 
Arabia. Methods: Charts from 455 adults with T2DM who visited the King Fahad 
National Guard Hospital from October 2009 to March 2010 (enrolment period) were 
systematically sampled until the target (n= 250) was reached. Haemoglobin A1c 
(HbA1c), LDL, and BP test results from enrolment to September 2011 were abstracted. 
The most recent test values were compared to guideline targets. The proportion 
of well-controlled (target met on all tests) and never-controlled (target not met on 
any test) subjects over the study period was calculated. Analyses were stratified 
by T2DM duration. Results: Forty-four percent of the cohort was male; at enrol-
ment, mean (SD) age was 61 (13) years and mean T2DM duration was 11 (8) years. 
At the most recent assessment, 36 subjects (14%) had HbA1c < 7%, 91 (36%) had 
HbA1c ≥ 9%, and 177 (72%) had LDL < 100mg/dL. Although 109 subjects (44%) met 
BP targets (< 130/80mmHg), 30% had BP ≥ 140/90mmHg. HbA1c, LDL and BP were 
well-controlled in 5.2%, 45.9%, and 8.4% of subjects, respectively, while 71.2%, 13.4% 
and 22.9% were never-controlled, respectively. The proportion of the cohort that 
was never-controlled for HbA1c increased with T2DM duration. ConClusions: 
While rates of HbA1c control were low among subjects with T2DM, nearly half met 
BP targets and nearly three quarters met LDL targets. Given the increased risk of 
complications associated with poor control, achieving higher rates of control could 
reduce the burden of T2DM in Saudi Arabia.
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objeCtives: To quantify the number and costs of relapses avoided over 2 
years in the first-line treatment of RRMS based on the findings of the Cochrane 
report. Methods: An Excel-based financial model estimated the relapses and costs 
incurred by a hypothetical cohort of 1000 RRMS patients treated with first-line 
disease-modifying drugs (DMDs). The modelled cohort evaluated the consequences 
of treatment with subcutaneous (SC) interferon beta-1a versus intramuscular 
(IM) interferon beta-1a, as this was the only comparison whose data quality was 
assessed as ‘high’ by the Cochrane Review (Filippini et al., 2013). Risk of relapse 
was based on the 2-year data from the Cochrane Review network meta-analysis. 
The analysis was performed from a US payer perspective. The cost of a relapse was 
sourced from Panitch et al., 2005, and adjusted to 2012 US dollars. Net annual cost 
of therapy was based on wholesale acquisition cost. Given the model’s short time 
horizon, disability-related costs were not included as these tend to be an important 
economic driver only over the long-term progression of the disease. In order to test 
how variability in the model’s inputs might impact the analysis’ results, two-way 
sensitivity analyses were performed based on the reported 95% risk of relapse cred-
ible intervals for SC interferon beta-1a and IM interferon beta-1a. Results: In a 
hypothetical cohort of 1000 RRMS patients, treatment with SC interferon beta-1a 
is expected to result in the avoidance of 173 (sensitivity analysis range: -20 to 399) 
relapses versus IM interferon beta-1a over 2 years. Assuming a direct cost of relapse 
of $5141, this represents a savings of $890,212 (sensitivity analysis range: -$102,138 
to $2,052,934) versus IM interferon beta-1a. ConClusions: Subcutaneous inter-
feron beta-1a is likely to result in fewer relapses and lower direct costs of relapse 
versus IM interferon beta-1a over a 2-year period treatment.
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objeCtives: To conduct decision-focused mixed treatment comparisons (MTCs) 
of the relative efficacy and safety of a new DPP-4 inhibitor (DPP-4i), alogliptin 25mg 
daily compared to current DPP-4i’s used in UK clinical practice (sitagliptin, saxa-
gliptin, linagliptin, vildagliptin) in dual therapy for the treatment of type 2 diabetes 
mellitus (T2DM) in combination with metformin or sulfonylurea (SU). Methods: A 
decision-focused systematic review was conducted to identify RCTs comparing the 
DPP-4i’s in combination with metformin or SU compared to metformin or SU alone 
or against each other in the target patient population. Separate Bayesian MTCs were 
conducted for each DPP-4i combination. Outcomes of interest were change in HbA1c 
from baseline (primary), weight change, proportion of patients HbA1c < 7%, and 
proportion of patients ≥ 1 hypoglycaemic episode. Fixed and random effects models 
were run with sensitivity analysis conducted to account for confounding factors 
(study length, baseline HbA1c), study heterogeneity and inconsistency. Results: 
Twenty-five RCTs met inclusion criteria for the MTCs. For the primary outcome, 
fixed effects models suffered from heterogeneity problems whilst random effect 
models struggled to estimate between trial heterogeneity. However, the base case 
and all sensitivity analyses showed the same results - alogliptin in combination with 
metformin or SU had a high probability of non-inferiority to comparator DPP-4’s in 
HbA1c change (61%-100% at a 0.3% HbA1cmargin). Deletion of trial outliers via lever-
age plots vastly improved model fit within fixed effects models whilst not changing 
underlying results. For all other outcomes alogliptin was shown to be comparable to 
alternative DPP-4i’s. ConClusions: Alogliptin 25mg has comparable efficacy and 
safety as other DPP-4i’s at their recommended doses in UK clinical practice. This 
is in line with expectations based on prior meta-analyses of DPP-4i’s. The use of a 
decision-focused approach to the MTC enables a focus on the data of direct interest 
for clinical and HTA based decision making.
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